Literature DB >> 10364271

Variants from the diverse virus population identified at seroconversion of a clade A human immunodeficiency virus type 1-infected woman have distinct biological properties.

M Poss1, J Overbaugh.   

Abstract

Development of effective therapeutics to prevent new infections with human immunodeficiency type 1 (HIV-1) is predicated on an understanding of the properties that provide a selective advantage to a transmitted viral population. In contrast to the homogeneous virus population that typifies early HIV-1 infection of men, the viral population in women recently infected with clade A HIV-1 is genetically diverse, based on evaluation of the envelope gene. A longitudinal study of viral envelope evolution in several women suggested that representative envelope variants detected at seroconversion had distinct biological properties that affected viral fitness. To test this hypothesis, a full-length, infectious molecular clone, Q23-17, was obtained from an infected woman 1 year following seroconversion, and chimeric viruses containing envelope genes representative of seroconversion and 27-month-postseroconversion populations were constructed. Dendritic cells (DC) could transfer infection of seroconversion variant Q23ScA, which dominated the viral population in the year following seroconversion, and the closely related 1-year isolate Q23-17 to resting peripheral blood mononuclear cells (PBMC). In contrast, resting PBMC exposed to DC pulsed with Q23ScB, which was detected infrequently in samples after seroconversion, or the 27-month chimeras were inconsistently infected. Additionally, quiescent PBMC infected with Q23ScA or Q23-17 proliferated more robustly than uninfected cells or cells infected with the other envelope chimeras in response to immobilized anti-CD3. Stimulation with tetanus toxoid led to an increased proportion of CD45RA+ cells and a decreased expression of CD28 on CD45RO+ cells in cultures of Q23-17-infected PBMC. These data demonstrate that variants from the heterogeneous seroconversion clade A HIV-1 population in a Kenyan woman have distinct biological features that may influence viral pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10364271      PMCID: PMC112580     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  76 in total

1.  HIV pathogenesis. Lines drawn in epitope wars.

Authors:  J M Coffin
Journal:  Nature       Date:  1995-06-15       Impact factor: 49.962

2.  Exponential increases of RNA virus fitness during large population transmissions.

Authors:  I S Novella; E A Duarte; S F Elena; A Moya; E Domingo; J J Holland
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

3.  Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays.

Authors:  E L Delwart; H W Sheppard; B D Walker; J Goudsmit; J I Mullins
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

4.  MEGA: Molecular Evolutionary Genetics Analysis software for microcomputers.

Authors:  S Kumar; K Tamura; M Nei
Journal:  Comput Appl Biosci       Date:  1994-04

5.  Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission.

Authors:  A B van't Wout; N A Kootstra; G A Mulder-Kampinga; N Albrecht-van Lent; H J Scherpbier; J Veenstra; K Boer; R A Coutinho; F Miedema; H Schuitemaker
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

6.  Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro.

Authors:  C A Spina; J C Guatelli; D D Richman
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

7.  Conjugates of dendritic cells and memory T lymphocytes from skin facilitate productive infection with HIV-1.

Authors:  M Pope; M G Betjes; N Romani; H Hirmand; P U Cameron; L Hoffman; S Gezelter; G Schuler; R M Steinman
Journal:  Cell       Date:  1994-08-12       Impact factor: 41.582

8.  The role of CD40 and CD80 accessory cell molecules in dendritic cell-dependent HIV-1 infection.

Authors:  L M Pinchuk; P S Polacino; M B Agy; S J Klaus; E A Clark
Journal:  Immunity       Date:  1994-07       Impact factor: 31.745

9.  In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus.

Authors:  M J Dolan; M Clerici; S P Blatt; C W Hendrix; G P Melcher; R N Boswell; T M Freeman; W Ward; R Hensley; G M Shearer
Journal:  J Infect Dis       Date:  1995-07       Impact factor: 5.226

10.  Generation of antigen-specific CD4+ T cell lines from naive precursors.

Authors:  A Mehta-Damani; S Markowicz; E G Engleman
Journal:  Eur J Immunol       Date:  1995-05       Impact factor: 5.532

View more
  44 in total

1.  Short Communication: Analysis of Minor Populations of Human Immunodeficiency Virus by Primer Identification and Insertion-Deletion and Carry Forward Correction Pipelines.

Authors:  Paul Hughes; Wenjie Deng; Scott C Olson; Robert W Coombs; Michael H Chung; Lisa M Frenkel
Journal:  AIDS Res Hum Retroviruses       Date:  2015-12-15       Impact factor: 2.205

2.  Shedding-Resistant HIV-1 Envelope Glycoproteins Adopt Downstream Conformations That Remain Responsive to Conformation-Preferring Ligands.

Authors:  Maolin Lu; Xiaochu Ma; Nick Reichard; Daniel S Terry; James Arthos; Amos B Smith; Joseph G Sodroski; Scott C Blanchard; Walther Mothes
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

3.  The ability of primate lentiviruses to degrade the monocyte restriction factor SAMHD1 preceded the birth of the viral accessory protein Vpx.

Authors:  Efrem S Lim; Oliver I Fregoso; Connor O McCoy; Frederick A Matsen; Harmit S Malik; Michael Emerman
Journal:  Cell Host Microbe       Date:  2012-01-26       Impact factor: 21.023

4.  Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity.

Authors:  Manish Sagar; Xueling Wu; Sandra Lee; Julie Overbaugh
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

5.  Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1.

Authors:  Rong Rong; S Gnanakaran; Julie M Decker; Frederic Bibollet-Ruche; Jesse Taylor; Jeffrey N Sfakianos; John L Mokili; Mark Muldoon; Joseph Mulenga; Susan Allen; Beatrice H Hahn; George M Shaw; Jerry L Blackwell; Bette T Korber; Eric Hunter; Cynthia A Derdeyn
Journal:  J Virol       Date:  2007-03-14       Impact factor: 5.103

6.  Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies.

Authors:  Michael S Seaman; Holly Janes; Natalie Hawkins; Lauren E Grandpre; Colleen Devoy; Ayush Giri; Rory T Coffey; Linda Harris; Blake Wood; Marcus G Daniels; Tanmoy Bhattacharya; Alan Lapedes; Victoria R Polonis; Francine E McCutchan; Peter B Gilbert; Steve G Self; Bette T Korber; David C Montefiori; John R Mascola
Journal:  J Virol       Date:  2009-11-25       Impact factor: 5.103

7.  Virus population homogenization following acute human immunodeficiency virus type 1 infection.

Authors:  Gerald H Learn; David Muthui; Scott J Brodie; Tuofu Zhu; Kurt Diem; James I Mullins; Lawrence Corey
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

8.  The neutralization sensitivity of viruses representing human immunodeficiency virus type 1 variants of diverse subtypes from early in infection is dependent on producer cell, as well as characteristics of the specific antibody and envelope variant.

Authors:  Nicholas M Provine; Valerie Cortez; Vrasha Chohan; Julie Overbaugh
Journal:  Virology       Date:  2012-02-25       Impact factor: 3.616

9.  Compartmentalization of human immunodeficiency virus type 1 between blood monocytes and CD4+ T cells during infection.

Authors:  Jennifer A Fulcher; Yon Hwangbo; Rafael Zioni; David Nickle; Xudong Lin; Laura Heath; James I Mullins; Lawrence Corey; Tuofu Zhu
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection.

Authors:  Behzad Etemad; Angela Fellows; Brenda Kwambana; Anupa Kamat; Yang Feng; Sandra Lee; Manish Sagar
Journal:  J Virol       Date:  2009-07-22       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.